Literature DB >> 8732950

Scaling basic toxicokinetic parameters from rat to man.

K Bachmann1, D Pardoe, D White.   

Abstract

Scaling of the quantified dispositional parameters of xenobiotics from animals to man is of interest from the standpoint of toxicology (e.g., poisoning and risk assessment). Scaling is also important from the standpoint of therapeutics because it represents a strategy for predicting first-use-in-human doses in clinical trials of investigational new drugs. Current strategies for scaling either doses of xenobiotics or the dispositional parameters of xenobiotics from animals to man rely on models that take account principally of species differences in weight or body surface area. Interspecies scaling of dispositional parameters such as clearance or volume of distribution commonly involves the comparison of estimates of these parameters for a given xenobiotic among numerous species on the basis of weight with the resultant mathematical relationship used to predict the values of those parameters for that xenobiotic in a species weighing, on average, about 70 kg (i.e., a man). Our approach has been to ascertain whether a useful mathematical model could be developed for predicting the dispositional parameters of a xenobiotic, its half-life and volume of distribution, in humans based exclusively on estimates of those parameters in rats. Based on a data set of about 100 different xenobiotics, we found that values for half-life and volume of distribution of a xenobiotic in humans can be predicted from the estimates of those parameters in rats.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8732950      PMCID: PMC1469326          DOI: 10.1289/ehp.96104400

Source DB:  PubMed          Journal:  Environ Health Perspect        ISSN: 0091-6765            Impact factor:   9.031


  139 in total

1.  Effect of age on the gastrointestinal absorption of acyclovir in rats.

Authors:  Y Fujioka; N Mizuno; E Morita; H Motozono; K Takahashi; Y Yamanaka; D Shinkuma
Journal:  J Pharm Pharmacol       Date:  1991-07       Impact factor: 3.765

2.  Felbamate pharmacokinetics in the rat, rabbit, and dog.

Authors:  V E Adusumalli; J T Yang; K K Wong; N Kucharczyk; R D Sofia
Journal:  Drug Metab Dispos       Date:  1991 Nov-Dec       Impact factor: 3.922

3.  Modeling of the effect site equilibration kinetics and pharmacodynamics of racemic baclofen and its enantiomers using quantitative EEG effect measures.

Authors:  J W Mandema; C D Heijligers-Feijen; E Tukker; A G De Boer; M Danhof
Journal:  J Pharmacol Exp Ther       Date:  1992-04       Impact factor: 4.030

4.  Pharmacodynamics and pharmacokinetics of intravenously administered morphine in spontaneously hypertensive and normotensive Wistar-Kyoto rats.

Authors:  H N Bhargava; V M Villar
Journal:  J Pharmacol Exp Ther       Date:  1992-04       Impact factor: 4.030

5.  Pharmacokinetics of cefpirome administered intravenously or intramuscularly to rats and dogs.

Authors:  D Isert; N Klesel; M Limbert; A Markus; G Seibert; E Schrinner
Journal:  J Antimicrob Chemother       Date:  1992-04       Impact factor: 5.790

6.  A population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat.

Authors:  L Aarons; J W Mandema; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1991-10

7.  Facile hydrolysis of mebeverine in vitro and in vivo: negligible circulating concentrations of the drug after oral administration.

Authors:  R G Dickinson; P V Baker; M E Franklin; W D Hooper
Journal:  J Pharm Sci       Date:  1991-10       Impact factor: 3.534

8.  Antipyrine kinetics in undernourished diabetics.

Authors:  J C Shobha; T C Raghuram; A D Kumar; K Krishnaswamy
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  The pharmacokinetics of flurbiprofen in younger and elderly patients with rheumatoid arthritis.

Authors:  W F Kean; E J Antal; E M Grace; H Cauvier; J Rischke; W W Buchanan
Journal:  J Clin Pharmacol       Date:  1992-01       Impact factor: 3.126

10.  Prediction of the disposition of propafenone in humans and dogs from pharmacokinetic parameters in other animal species.

Authors:  A Puigdemont; R Guitart; F de Mora; M Arboix
Journal:  J Pharm Sci       Date:  1991-12       Impact factor: 3.534

View more
  18 in total

Review 1.  Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations.

Authors:  T Lavé; P Coassolo; B Reigner
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

2.  Ellagic acid attenuates high-carbohydrate, high-fat diet-induced metabolic syndrome in rats.

Authors:  Sunil K Panchal; Leigh Ward; Lindsay Brown
Journal:  Eur J Nutr       Date:  2012-04-27       Impact factor: 5.614

3.  Low dose of donepezil improves gabapentin analgesia in the rat spared nerve injury model of neuropathic pain: single and multiple dosing studies.

Authors:  Anna Folkesson; Per Hartvig Honoré; Lene Munkholm Andersen; Pernille Kristensen; Ole J Bjerrum
Journal:  J Neural Transm (Vienna)       Date:  2010-10-02       Impact factor: 3.575

4.  A microfluidic 3D hepatocyte chip for hepatotoxicity testing of nanoparticles.

Authors:  Lei Li; Kurtulus Gokduman; Aslihan Gokaltun; Martin L Yarmush; Osman Berk Usta
Journal:  Nanomedicine (Lond)       Date:  2019-06-10       Impact factor: 5.307

5.  The use of the suicide CYP450 inhibitor ABT for distinguishing absorption and metabolism processes in in-vivo pharmacokinetic screens.

Authors:  Gary W Caldwell; David M Ritchie; John A Masucci; William Hageman; Carlos Cotto; Jeffrey Hall; Becki Hasting; William Jones
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jan-Jun       Impact factor: 2.441

6.  Towards a better prediction of peak concentration, volume of distribution and half-life after oral drug administration in man, using allometry.

Authors:  Vikash K Sinha; Karin Vaarties; Stefan S De Buck; Luca A Fenu; Marjoleen Nijsen; Ron A H J Gilissen; Wendy Sanderson; Kelly Van Uytsel; Eva Hoeben; Achiel Van Peer; Claire E Mackie; Johan W Smit
Journal:  Clin Pharmacokinet       Date:  2011-05       Impact factor: 6.447

7.  Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats.

Authors:  Hani Al-Salami; Grant Butt; Ian Tucker; Svetlana Golocorbin-Kon; Momir Mikov
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-08-28       Impact factor: 2.441

8.  Preclinical pharmacokinetics and interspecies scaling of ragaglitazar, a novel biliary excreted PPAR dual activator.

Authors:  Venkata V Pavankuamr; C A Vinu; Ramesh Mullangi; Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2007 Jan-Mar       Impact factor: 2.441

9.  Probiotic Pre-treatment Reduces Gliclazide Permeation (ex vivo) in Healthy Rats but Increases It in Diabetic Rats to the Level Seen in Untreated Healthy Rats.

Authors:  Hani Al-Salami; Grant Butt; Ian Tucker; Ranko Skrbic; Svetlana Golocorbin-Kon; Momir Mikov
Journal:  Arch Drug Inf       Date:  2008-07

10.  Allometric scaling of pharmacokinetic parameters in drug discovery: can human CL, Vss and t1/2 be predicted from in-vivo rat data?

Authors:  Gary W Caldwell; John A Masucci; Zhengyin Yan; William Hageman
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2004 Apr-Jun       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.